Wells Fargo Downgrades Fate Therapeutics to Market Perform, Lowers Price Target to $16

Wells Fargo downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Market Perform and lowers the price target from $24 to $16.

Benzinga · 11/06/2019 11:14

Wells Fargo downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Market Perform and lowers the price target from $24 to $16.